Crown Bioscience, NRCMM partner for cancer models
June 2014
by  |  Email the author


SANTA CLARA, Calif.—An agreement was struck in May between Crown Bioscience Inc. and the National Resource Center for Mutant Mice (NRCMM) in China for the development of new experimental cancer models to advance translational medical research and cancer treatment. Both partners bring with them experience in oncology, with NRCMM specializing in genetically engineered mutant mouse models and Crown Bioscience boasting one of the largest translational oncology platforms with fully annotated collections of proprietary patient-derived xenograft models. The companies will initially focus on developing the new models utilizing their respective proprietary technologies, with this agreement expected to expand both organizations’ translational oncology research capabilities and provide expanded new mouse cancer and leukemia models based on genetically engineered mice and new human xenografts. Dr. Jean-Pierre Wery, Crown’s president, noted that “This partnership will offer world-class translational oncology services, and ultimately benefit cancer patients around the world.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.